|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hypoglycemic mechanism of polysaccharide from Cyclocarya paliurus leaves in type 2 diabetic rats by gut microbiota and host metabolism alteration显示文摘Diabetes mellitus is a serious threat to human health.Cyclocarya paliurus(Batal.)Iljinskaja(C.paliurus)is one of the traditional herbal medicine and food in China for treating type 2 diabetes,and the C.paliurus polysaccharides(CP)were found to be one of its major functional constituents.This research aimed at investigating the hypoglycemic mechanism for CP.It was found that CP markedly attenuated the symptoms of diabetes,and inhibited the protein expression of Bax,improved the expression of Bcl-2 in pancreas of diabetic rats,normalized hormones secretion and controlled the inflammation which contributed to the regeneration of pancreaticβ-cell and insulin resistance.CP treatment increased the beneficial bacteria genus Ruminococcaceae UCG-005 which was reported to be a key genus for protecting against diabetes,and the fecal short-chain fatty acids levels were elevated.Uric metabolites analysis showed that CP treatment helped to protect with the diabetes by seven significantly improved pathways closely with the nutrition metabolism(amino acids and purine)and energy metabolism(TCA cycle),which could help to build up the intestinal epithelial cell defense for the inflammation associated with the diabetes.Our study highlights the specific mechanism of prebiotics to attenuate diabetes through multi-path of gut microbiota and host metabolism. | Qiqiong Li Jielun Hu Qixing Nie Xiao Chang Qingying Fang Junhua Xie Haishan Li Shaoping Nie | 2021 | Science China(Life Sciences)2021，64，1： | 11 |
| 2 | 生物制剂治疗银屑病的研究进展显示文摘银屑病是一种慢性炎症性皮肤病,免疫细胞成分和细胞因子均在银屑病的发病中发挥了重要作用.近年来,靶向作用于TNF-α,IL-12/23,IL-17,IL-23的生物制剂,在中重度银屑病的治疗中有着广泛应用.本文对生物制剂治疗银屑病的研究进展进行了综述,主要包括药物种类、安全性、药物失效与药物停用、联合用药、疗效预测与药物转换、新药与基础研究进展等方面,为该领域的发展,如联合治疗、新药研究等方面提供参考.最后,对北京协和医院皮肤科在银屑病的基础研究及临床诊疗等方面的工作进行了综述. | 张翰林 舒畅 晋红中 | 2021 | 中国科学:生命科学2021，51，8： | 10 |
| 3 | 肠微生态移植重建治疗重度银屑病的临床研究显示文摘通过肠微生态移植重建(FMT)治疗重度银屑病,探索治疗银屑病的新方法.患者男,36岁,患寻常型银屑病10年,肠易激综合征15年,进行2次胃、肠镜联合FMT治疗.评估治疗前后皮损累及体表面积(BSA)、银屑病面积和严重程度指数(PASI)、生活质量指数(DLQI)、皮肤组织病理、肠道症状、安全性及血清肿瘤坏死因子α等.结果显示,FMT治疗该例银屑病患者临床疗效显著,肠易激综合征临床症状消失,且无不良反应发生.提示FMT可能是治疗银屑病的一种新疗法,值得进一步研究. | 殷广 李剑锋 孙玉发 丁潇 曾嘉琦 张婷 彭丽华 杨云生 赵华 | 2019 | 中华内科杂志2019，58，10： | 7 |
| 4 | 肠道菌群与银屑病相关性的实验研究进展显示文摘银屑病是一种常见的、免疫介导的慢性、复发性、炎症性、系统性皮肤病。近年来,随着对肠道菌群研究的深入,其与人体健康、疾病的关系也日益受到重视。研究表明,肠道菌群与银屑病发生、发展、转归等密切相关。本文总结了近年来的文献,以肠皮肤轴为切入点,针对肠道菌群与银屑病之间的相互关系作一综述。 | 徐晓蓉 龚坚 王婧 吴嘉明 刘巧 | 2020 | 实用医学杂志2020，36，9： | 5 |
| 5 | 银屑病免疫学发病机制与生物制剂治疗显示文摘银屑病发病机制复杂,与机体的免疫系统功能紊乱密切相关,患者外貌和身体机能均受到严重损害,病情反复发作,极难根治,严重影响患者的身心健康和学习工作。但随着研究的深入和技术的发展,不少生物制剂被批准用于银屑病患者的临床治疗并取得了比较满意的效果。本文就银屑病的免疫学发病机制和一些生物制剂的治疗原理、效果、不良反应、应用原则等进行综述,旨为临床治疗银屑病提供参考。 | 黎奕江 江文宇 | 2022 | 内科2022，17，3： | 4 |
| 6 | Distinct lung microbial community states in patients with pulmonary tuberculosis显示文摘An improved understanding of the lung microbiome may lead to better strategies to diagnose, treat, and prevent pulmonary tuberculosis (PTB). However, the characteristics of the lung microbiomes of patients with TB remain largely undefined. In this study, 163 bronchoalveolar lavage (BAL) samples were collected from 163 sputum-negative suspected PTB patients. Furthermore, 12 paired BAL samples were obtained from 12 Mycobacterium tuberculosis-positive (MTB+) patients before and after negative conversion following a two-month anti-TB treatment. The V3–V4 region of the 16S ribosomal RNA (rRNA) gene was used to characterize the microbial composition of the lungs. The results showed that the prevalence of MTB in the BAL samples was 42.9% (70/163) among the sputum-negative patients. The α-diversity of lung microbiota was significantly less diverse in MTB+ patients compared with Mycobacterium tuberculosis-negative (MTB–) patients. There was a significant difference in β-diversity between MTB+ and MTB– patients. MTB+ patients were enriched with Anoxybacillus, while MTB– patients were enriched with Prevotella, Alloprevotella, Veillonella, and Gemella. There was no significant difference between the Anoxybacillus detection rates of MTB+ and MTB– patients. The paired comparison between the BAL samples from MTB+ patients and their negative conversion showed that BAL negative-conversion microbiota had a higher α-diversity. In conclusion, distinct features of airway microbiota could be identified between samples from patients with and without MTB. Our results imply links between lung microbiota and different clinical groups of active PTB. | Yongfeng Hu Ying Kang Xi Liu Min Cheng Jie Dong Lilian Sun Yafang Zhu Xianwen Ren Qianting Yang Xinchun Chen Qi Jin Fan Yang | 2020 | Science China(Life Sciences)2020，63，10： | 1 |
| 7 | 饮食、肠道菌群与银屑病显示文摘银屑病是常见的慢性炎症性皮肤病之一,饮食与其发病、治疗及转归密切相关;随着对肠道菌群与银屑病相关性研究的深入,将饮食、肠道菌群、银屑病三者紧密联系在一起.该文从肠道菌群与银屑病关系及饮食调控肠道菌群治疗银屑病的研究进行综述,以期为银屑病相关研究及临床饮食指导提供参考. | 龚坚 刘巧 | 2021 | 实用皮肤病学杂志2021，14，6： | 0 |
| 8 | 银屑病患者与健康人肠道菌群的差异研究显示文摘目的探讨银屑病患者与健康人肠道菌群差异。方法收集我院2018年8~12月银屑病患者(PSO组)及健康人群(CON组)粪便样本各10例,采用16S rRNA测序并用信息学方法分析两组肠道菌群差异。结果银屑病患者及健康人肠道菌群中关键菌群有差异,目、科水平:PSO组肠杆菌目及木霉菌目(Streptophyta)、肠杆菌科及未分类木酶菌科(unclassified Streptophyta)丰度较CON组高(P<0.05);属水平:PSO组瘤胃球菌(Ruminococcus)丰度较CON组高(P<0.05);种水平:PSO组埃氏拟杆菌(Bacteroides eggerthii)、Clostridium ruminantium菌种丰度较CON组丰度低(P<0.05)。组间差异群落分析显示,肠杆菌科、瘤胃球菌属等菌群是银屑病患者菌群失衡的关键类型。结论与健康人肠道菌群相比,银屑病患者肠道中肠杆菌科、瘤胃球菌属丰度高,可能与银屑病的发病机制有关。 | 王小康 朱晓芳 | 2023 | 中国现代医药杂志2023，25，3： | 0 |
| 9 | 肠道菌群失调与银屑病的相关性研究进展显示文摘目的银屑病是一种慢性、复发性、全身炎性反应疾病,与遗传相关。在遗传倾向上,一些环境因素,包括细菌感染、抗生素治疗或饮食的变化,可以导致肠道菌群的变化。越来越多的证据表明,肠道和皮肤之间存在联系,即肠-皮肤轴,该轴同样存在于银屑病患者中。肠道菌群的失调可能会改变系统免疫,导致体内平衡失调和皮肤功能受损。阐明肠道微生物与宿主之间的相互作用有助于了解银屑病的发病机制,为开发新型的微生物靶向治疗提供基础。笔者就肠道菌群与银屑病发病的生物学性状、皮肤稳态和异构化作用、相关性及肠道菌群治疗进展进行综述。 | 高双双 王渟 范华宇 刘洋爱 陈晋广 | 2022 | 中国中西医结合皮肤性病学杂志2022，21，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员